Aortic Valve Disease Clinical Trial
— TiAraOfficial title:
Post-market Clinical Monitoring of the Safety and Efficacy of the Aortic Valve Bioprothesis "Đ¢iAra" (T-ara)
The goal of this multicenter prospective cohort study is to evaluate the long-term safety and efficacy of clinical outcomes of aortic valve replacement using the "TiAra" prosthesis with or without concomitant procedures. Main research objectives: 1. To analyze the short and mid-term (up to 3 years) outcome of aortic valve replacement using the "TiAra" prosthesis. 2. To study the hemodynamic characteristics of normally functioning "TiAra" prostheses in the aortic position, as well as the condition of the heart chambers in short and long-term period (up to 10 years) after the implantation. 3. To assess complications of the early and mid-term follow-up periods of aortic valve replacement using the "TiAra" prosthesis. This study does not presuppose implementation of comparison groups.
Status | Recruiting |
Enrollment | 2000 |
Est. completion date | August 10, 2024 |
Est. primary completion date | August 10, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 60 Years to 70 Years |
Eligibility | Inclusion Criteria: 1. The patient's written consent to participate in the study and the absence of restrictions on physical movement (diseases of the musculoskeletal system and diseases of the central nervous system, accompanied by cognitive disorders (disorientation, inability to independently reach the destination). 2. The patient is a resident of the city* (suburb) where the institution is conducting study. * - participation is also possible for those living in the rural areas, but they have to be able to make visits to the Research Center. 3. Age: 60-70 years old with a life expectancy of 3 years or more. Or a person younger than 60 with contraindications to taking anticoagulants, or with increased risk of their use, consciously choosing a biological prosthesis for valve replacement. 4. Isolated aortic valve disease. 5. Real intervention on the heart valve is primary. 6. Absence of concomitant interventions on the heart and thoracic aorta**. ** - Coronary artery bypass grafting, correction of tricuspid valve disease, previously treated congenital heart defects, aortic intervention 7. The intervention on the valve is planned (that is, it is not carried out in expedited/urgent manner or is not a "rescue" operation). 8. Absence of acute and subacute infective endocarditis. 9. The following factors should not be present before surgery: high pulmonary hypertension (pulmonary arterial systolic pressure more than 60 mmHg), functional class 4 (according to the New York Heart Association Functional Classification) while in ongoing treatment, left ventricular ejection fraction less than 30%. Exclusion Criteria: 1. The presence of severe somatic, neurological, mental diseases and infectious diseases that worsen the prognosis of long-term survival (ischemic heart disease, tuberculosis, human immunodeficiency viruses, Alzheimer's disease, epilepsy, insulin-requiring diabetes, kidney disease with creatinine clearance less than 85 mL/min, chronic lung disease requiring chronic corticosteroids and bronchodilators, multifocal atherosclerosis (intermittent claudication, carotid arteries stenosis of more than 50%, prior and planned interventions on abdominal area, carotid arteries or arteries of the lower extremities). 2. The patient has any not related to the underlying cardiovascular system disease pathology that will lead to the death of the patient in less than 1 year. 3. The patient is currently participating in a study of a new drug or other medical devices. |
Country | Name | City | State |
---|---|---|---|
Russian Federation | Research Institute for Complex Problems of Cardiovascular Diseases, Russia | Kemerovo | Kemerovo Region |
Lead Sponsor | Collaborator |
---|---|
Closed Joint-Stock Company NeoCor | CT Medical Limited Liability Company, Research Institute for Complex Problems of Cardiovascular Diseases, Russia |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 1. Incidence of Treatment-Emergent Adverse Events, requiring repeated surgical intervention in the long term (long-term safety and durability) | Long-term safety of the "TiAra" epoxy-treated prosthesis made with xenopericardium will be evaluated by the frequency of complications associated with the valve.
Device safety is defined as the absence of severe adverse events associated with the device or procedure, assessed by the following clinical phenomena: Death Severe complications of the heart Life-threatening bleeding Any bioprosthesis-related dysfunction, migration, thrombosis or other complication requiring an open-heart surgery or repeated intervention. Myocardial infarction or progression of a chronic form of ischemia requiring percutaneous coronary intervention and coronary artery bypass grafting Access site complications Stroke |
Up to 12 years from the moment of implantation . | |
Primary | 2. Incidence of Treatment-Emergent Adverse Events, requiring repeated surgical intervention in the short term (short-term safety) | Short-term safety of the "TiAra" epoxy-treated prosthesis made with xenopericardium in the treatment of isolated mitral and aortic valve diseases will be evaluated by the frequency of complications associated with the valve.
Device safety is defined as the absence of severe adverse events associated with the device or procedure, assessed by the following clinical phenomena: hemolysis hemolytic anemia a heart stroke myocardial infarction hemorrhaging and bleeding heart arrhythmia nonstructural dysfunction pannus prosthesis-patient mismatch dislocation paraprosthetic and transprosthetic regurgitation heart failure breast-pang structural deterioration valve thrombosis thromboembolism encarditis a reoperation |
Up to 12 years from the moment of implantation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04149600 -
Identification of Genetic Causes of Calcific Aortic Valve Disease
|
||
Recruiting |
NCT06001489 -
The Effects of 360-degree Virtual Reality on Pre-procedural Anxiety in Patients Awaiting Elective Cardiac Surgery Involving a Sternotomy
|
N/A | |
Not yet recruiting |
NCT04430972 -
Immune Responsiveness and Outcome After Aortic Valve Surgery (Measure)
|
||
Completed |
NCT02467062 -
Implementation of Non-size Markers Derived From 4D Flow MRI of Patients With Aortic Disease.
|
N/A | |
Not yet recruiting |
NCT02221921 -
Safety and Efficacy Study of MicroPort's Transcatheter Aortic Valve and Delivery System for TAVI
|
N/A | |
Terminated |
NCT02128841 -
Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.
|
Phase 2 | |
Active, not recruiting |
NCT01194362 -
A Study to Identify Differences in Gene Expression in Patients With Bicuspid and Tricuspid Valve Disease
|
||
Not yet recruiting |
NCT05975567 -
Deploying Novel Imaging Modalities Towards a Three-dimensional (3D) CARDIOvascular PATHology
|
||
Recruiting |
NCT06025149 -
The Study on the Use of "UniLine" Bioprosthesis in the Treatment of Isolated Aortic and Mitral Valve Diseases
|
||
Completed |
NCT05082337 -
The SAVVY Guidewire in Transcatheter Aortic Valve Replacement Procedures
|
N/A | |
Completed |
NCT05193760 -
Robustness Check of Placement and Measurement Algorithms for Blood Flow Measurement on Common Carotid Artery
|
||
Not yet recruiting |
NCT05941455 -
A Prospective Multicenter Pivotal Study to Evaluate Safety and Effectiveness of Venus-Neo Surgical Aortic Valve
|
N/A | |
Active, not recruiting |
NCT04950192 -
Philips Intracardiac Echocardiography (ICE) Clinical Registry
|
||
Active, not recruiting |
NCT03924661 -
SJM Masters HP 15mm Rotatable Mechanical Heart Valve as Aortic Valve Replacement Therapy
|
||
Completed |
NCT04073875 -
18F-GP1 PET-CT to Detect Bioprosthetic Aortic Valve Thrombosis
|
||
Recruiting |
NCT03121053 -
Preventing contrAst Induced Nephropathy After TranscathEter Aortic Valve Replacement
|
Phase 4 | |
Completed |
NCT02000544 -
Clinical Evaluation of a Modular Extracorporeal Circulation Circuit
|
N/A | |
Completed |
NCT02688153 -
EDWARDS INTUITY Valve System CADENCE Study
|
N/A | |
Completed |
NCT02981004 -
PAR I - Patient-to-Annulus Relation I
|
||
Recruiting |
NCT06126367 -
Assessment of Lipoprotein(a) and Endogenous Fibrinolysis in Atherosclerotic Cardiovascular Disease/Aortic Valve Disease
|